Last updated on September 2018

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Brief description of study

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Clinical Study Identifier: NCT02857270

Contact Investigators or Research Sites near you

Start Over

Manish Rajni Patel

Florida Cancer Specialists
Sarasota, FL United States
  Connect »

Ryan Sullivan

Massachusetts General Hospital
Boston, MA United States
  Connect »

Sarah Cannon Research Inst.

Sarah Cannon Cancer Center
Nashville, TN United States
  Connect »

Johanna Chock Bendell

Tennessee Oncology PLLC
Nashville, TN United States
  Connect »

Shubham Pant

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Stephen V Liu

Georgetown University Medical Center
Washington, WA United States
  Connect »

Konstantin Dragnev

Dartmouth Hitchcock Medical Center
Lebanon, NH United States
  Connect »

Timothy F Burns

UPMC Hillman Cancer Center
Pittsburgh, PA United States
  Connect »

Anthony Joshua

St Vincent's Hospital
Sydney, Australia
  Connect »

Michael J Millward

Linear Clinical Research Ltd
Nedlands, Australia
  Connect »

Antoine Hollebecque

Gustave Roussy
Villejuif Cedex, France
  Connect »